In mismatch-repair-proficient or microsatellite instability-low (pMMR-MSI-L) CRC and melanoma mouse models, depletion of METTL3 enhances the tumor response to anti-PD-1 treatment through stabilizing the Stat1 and Irf1 mRNA via YTHDF2 [100] (Figure 3). Here, METTL3 is linked to melanoma.